West Pharmaceutical Services (NYSE:WST - Get Free Report) released its earnings results on Thursday. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29, Zacks reports. The company had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.43% and a net margin of 16.48%.West Pharmaceutical Services's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.85 earnings per share. West Pharmaceutical Services updated its FY 2025 guidance to 7.060-7.110 EPS.
West Pharmaceutical Services Stock Performance
Shares of West Pharmaceutical Services stock traded up $31.99 during trading hours on Thursday, reaching $308.99. The company had a trading volume of 591,046 shares, compared to its average volume of 797,854. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.78 and a quick ratio of 2.08. West Pharmaceutical Services has a one year low of $187.43 and a one year high of $352.33. The firm has a market cap of $22.22 billion, a PE ratio of 46.17, a price-to-earnings-growth ratio of 4.90 and a beta of 1.07. The business has a fifty day simple moving average of $257.04 and a 200 day simple moving average of $232.65.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on WST. Redburn Partners set a $311.00 price objective on West Pharmaceutical Services in a report on Monday, September 15th. Evercore ISI set a $350.00 price objective on West Pharmaceutical Services in a report on Tuesday, October 7th. Barclays increased their price objective on West Pharmaceutical Services from $260.00 to $275.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. Wall Street Zen raised West Pharmaceutical Services from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, Rothschild Redb raised West Pharmaceutical Services to a "strong-buy" rating in a report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $321.89.
Check Out Our Latest Analysis on WST
Institutional Investors Weigh In On West Pharmaceutical Services
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Benjamin Edwards Inc. grew its position in West Pharmaceutical Services by 1.7% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier's stock worth $661,000 after purchasing an additional 50 shares during the period. Modern Wealth Management LLC grew its position in shares of West Pharmaceutical Services by 7.4% during the 2nd quarter. Modern Wealth Management LLC now owns 1,270 shares of the medical instruments supplier's stock valued at $278,000 after acquiring an additional 87 shares during the period. CYBER HORNET ETFs LLC bought a new stake in shares of West Pharmaceutical Services during the 2nd quarter valued at $25,000. Acadian Asset Management LLC grew its position in shares of West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier's stock valued at $284,000 after acquiring an additional 157 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of West Pharmaceutical Services by 78.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier's stock valued at $98,000 after acquiring an additional 197 shares during the period. Hedge funds and other institutional investors own 93.90% of the company's stock.
About West Pharmaceutical Services
(
Get Free Report)
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider West Pharmaceutical Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.
While West Pharmaceutical Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
